Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485550 · ClinicalTrials.gov registry record · Phase 3
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT00485550 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 14 participants.
The verdict
NCT00485550, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.
Interventions
- DRUG Placebo
- DRUG Methylphenidate Hydrochloride
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00485550
The ClinicalTrials.gov registry entry for NCT00485550 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00485550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00485550 about?
NCT00485550 is a clinical study titled "Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy". The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.
What is the current status of trial NCT00485550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2004-01. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00485550?
The interventions under investigation include: Placebo (DRUG), Methylphenidate Hydrochloride (DRUG), Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00485550?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.